



























Telomere DNA repeats and telomerase: Classical 
view of telomere biology 
 
Chromosome ends have repetitive DNA sequences 
called telomere DNA repeats. The unit of the repeats is 
5’-TTAGGG-3’ in mammals, and the total length of the 
repeats reaches approximately 3 to 15 kilobase pairs 
(Kb) in humans, depending on cell types as well as 
other intrinsic and extrinsic factors. A major 
determinant of the telomere length in normal human 
differentiated cells (e.g., fibroblasts, which is a cell type 
most commonly used in cell culture experiments in 
vitro) is their replicative history, i.e., the number of cell 
divisions the cells have undergone [1]. Because of the 
inability of conventional DNA polymerases to replicate 
the very end of linear DNA molecules (so-called “end 
replication problem”), these normal cells experience a 
progressive decline in telomere length, as an indicator 
of “cellular aging”, in a cell division number-dependent 
manner. The presence of critically eroded telomeres in 
these cells is associated with the end of their replicative 
lifespan, a permanent growth arrest state called 
“replicative senescence” [1]. In contrast, germ cells, 
stem cells and cancer cells have a mechanism of 
synthesizing  telomere DNA  repeats  to compensate the  
 
 




























cell division-dependent telomere attrition, thereby 
bypassing the replicative senescence and being capable 
of self-replicating indefinitely [2]. Although ~10% of 
human cancers use a recombination-based mechanism 
(i.e., alternative lengthening of telomeres, ALT) [2], the 
major mechanism for telomere maintenance in human 
cells is the activation of a telomere G-rich strand-
synthesizing enzyme, telomerase, which consists of the 
catalytic protein subunit (human telomerase reverse 
transcriptase, hTERT), the RNA component (hTER) 
containing a C-rich template region, and other 
associated proteins [3]. During a transition from normal 
mortal cells to immortalized, transformed cells, the 
transcriptional activation of the hTERT  gene is a 
limiting step on which various cellular and viral 
oncogenic mechanisms act [4], including p53 
inactivation [5]. Consistently, an ectopic expression of 
hTERT could lead to immortalization of normal human 
cells [6], and inhibition of hTERT in immortalized 
cancer cells could induce them to undergo senescence 
[7]. All of these findings accumulated from 1980’s to 
late 1990’s have supported “telomere hypothesis of 
cellular aging” to explain replicative senescence and 
immortalization of human cells.  





















regulation  by  targeting  TRF2  for  ubiquitination  and  proteasomal  degradation.  Biological  significance  and  therapeutic
implications of this study are discussed.  
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Since mid-late 1990’s a growing body of evidence has 
established that not only telomere length but also its 
specific DNA structure is a key factor for normal 
telomere functions, and that a number of proteins 
associated with telomere DNA repeats play 
physiological roles at telomeres [8]. Telomere DNA 
was revealed to form a lariat structure, which is named 
“t-loop”, hiding chromosome ends into the structure and 
thus preventing them from undergoing illegitimate 
degradation or fusion events and from activating 
unwanted DNA damage signaling [9]. For the formation 
of this t-loop structure, a single-stranded, G-rich 3’-
overhang at the extreme end of telomere DNA repeats 
plays an essential role by invading the double-stranded 
part of the repeats. The coordinated synthesis and 
processing of C-rich strand are required for the 
generation of 3’-overhang and thus essential for the 
telomere-specific DNA structure [10].  
 
An increasing number of proteins have been shown to 
interact with telomere DNA repeats. Six of them (TRF1, 
TRF2, POT1, TIN2, TPP1 and RAP1) form a single 
telomere DNA-interacting complex, named “shelterin” 
[8]. TRF1 and TRF2 directly bind the double-stranded 
telomere repeats, POT1 directly binds to the single-
stranded 3’-overhang, and the other three components 
interconnect these telomere-binding components. The 
shelterin complex is indispensable for the formation and 
maintenance of the telomere-specific DNA structure 
described above, as well as for distinguished 
recognition of telomeres from broken DNA ends. 
Specifically, TRF2 has an activity to enhance the t-loop 
formation [11] and can prevent ATM (ataxia 
telangiectasia mutated) kinase from initiating the DNA 
damage signaling at functional telomeres [12]. TRF2 
interacts with ATM and inhibits its autophosphorylation 
critical for activation [13]. POT1 governs the integrity 
of telomere DNA ends at both G-rich 3’-overhang and 
C-rich 5’-recessed strand [14], as well as inhibits 
another DNA damage signaling kinase ATR (ATM- and 
Rad3-related) [12].  
 
Taken all these findings together, we now recognize 
telomeres as a DNA-multiprotein complex with specific 
structure and functions, rather than only as an end of 
linear DNA molecules, and the concept of “telomere 
capping” has been established. The “capped” state of 
telomeres is primarily attributed to the t-loop structure 
of telomere DNA repeats and the recruitment and 
function of the shelterin complex [8,9]. Functional 
inhibition or knockdown of the shelterin components 
such as TRF2 and POT1 thus induced the “uncapped”, 
or dysfunctional, state of telomeres, which was 
characterized by loss of 3’-overhang, telomere fusion-
induced chromosome instability and activated DNA 
damage signaling [15-17]. The classical view of 
telomere biology described above, however, still stands 
together with the updated view: either telomeres that are 
long enough (e.g., in normal, non-senescent cells) or 
activated telomerase (e.g., in cancer cells), or both (e.g., 
in germ cells and stem cells) could contribute to the 
strength and stable maintenance of the capped state of 
telomeres [18]. Long telomeres could provide a 
platform for enhanced recruitment of telomere-binding 
proteins (e.g., TRF2) and a high efficiency of t-loop 
formation in the absence of telomerase activity. The 
ability of telomerase to synthesize G-rich telomere 
DNA strand could generate 3’-overhang sufficient for 
short telomeres to form a t-loop. Consistently, the 
presence of neither long telomeres nor telomerase 
activity (for example, critically short telomeres at the 
end of replicative lifespan in telomerase-negative 
normal cells [19], and telomerase inhibition in cancer 
cells with short telomeres [20]) causes the telomere 
uncapping-associated phenotypes similar to those 
induced by inhibition of the shelterin components.  
 
p53 as a downstream effector of the telomere 
damage signaling  
 
The tumor suppressor protein p53 is activated by 
endogenous or exogenous DNA damage and other 
cellular stresses through its posttranslational 
modifications such as phosphorylation, acetylation and 
sumoylation [21]. The p53-induced cellular phenotypes 
include apoptotic cell death and cellular senescence, 
each of which functions as a tumor suppressor 
mechanism and may have a role in organismal aging 
[22]. Classically, along with the telomere hypothesis of 
cellular aging, inhibition of p53 allowed normal human 
fibroblasts to continue proliferating even with shorter 
telomeres than the threshold length, suggesting that p53 
was indispensable for the onset of telomere-initiated 
replicative cellular senescence [1]. With the concept of 
telomere capping, we now define uncapped or 
dysfunctional telomeres, which are functionally 
synonymous with eroded telomeres at the end of the 
cellular replicative lifespan [18,19], as an endogenous 
DNA damage that physiologically activates p53. Two 
major signaling kinases that phosphorylate and thereby 
activate p53 are ATM and ATR, which, as described 
above, are controlled by two shelterin components 
TRF2 and POT1, respectively [12]. ATM and p53 
mediate the telomere uncapping-induced apoptosis or 
cellular senescence (for example, apoptosis in 
lymphocytes [23] and cellular senescence in fibroblasts 
[24]), establishing the TRF2-ATM-p53 pathway as a 
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response initiated at uncapped telomeres. Although 
ATR may be less essential to telomere damage 
signaling in human cells with functional ATM and its 
downstream targets, it is still capable of inducing p53-
dependent cellular senescence independently of ATM 
[25]. Thus, the POT1-ATR-p53 pathway can also 
signal the DNA damage response from uncapped 
telomeres.  
 
p53 represses TRF2 protein levels through a p53-
inducible E3 ubiquitin ligase Siah1  
 
Comparing the expression profiles of endogenous 
mRNA or proteins in normal human cells at 
proliferating phase (referred “young”) versus at 
replicative senescence has identified a number of 
senescence-associated genes and proteins. Our cell 
system consists of an isogenic pair of young and 
replicatively senescent human fibroblasts, in the latter 
of which p53 activation is evidenced by its 
phosphorylation at serine 15 residue and the 
upregulation of p53 target genes such as p21
WAF1 
[26,27]. Among those identified by our previous studies 
using this cell system are: Δ133p53 and p53β (p53 
isoforms) [26], POT1v5 (a POT1 isoform) [17], ING2 
(a p53- and chromatin-interacting protein) [28], miR-
34a (a p53-inducible microRNA) [26], and WNT16B (a 
member of WNT family of secreted proteins) [29]. Our 
recent study [27] adds TRF2 to the list of proteins 
whose expression levels are changed during replicative 
senescence. The expression levels of TRF2 protein were 
reduced in replicatively senescent fibroblasts, but TRF2 
mRNA levels did not change, suggesting the regulation 
at a post-transcriptional or protein level. A series of 
experimental manipulation of p53 expression and 
activity, including spontaneous allelic loss, short hairpin 
RNA (shRNA)-mediated knockdown, dominant-
negative inhibition, nutlin-3a activation and retroviral 
overexpression, all suggested that p53 represses TRF2 
protein levels, again without a change in TRF2 mRNA 
expression.  
 
Siah1 is an E3 ubiquitin ligase with a C3HC4-type 
RING finger domain. The Siah1  gene is 
transcriptionally induced by p53 [30]. Siah1 targets 
proteins containing a Myb DNA-binding domain [31], 
which is present in TRF2 [15], for proteasome-mediated 
degradation. We have also found that TRF2 is a 
ubiquitinated protein and is subject to proteasome-
mediated degradation [27]. All of these findings 
prompted us to examine whether Siah1 is responsible 
for the p53-mediated repression of TRF2 at the protein 
level. In the replicative senescence with activated p53 
and all the experimental settings described above, Siah1 
expression levels (both mRNA and protein levels) were 
inversely correlated with TRF2 protein levels: TRF2 
upregulation was coincident with Siah1 downregulation 
when p53 was lost or inhibited; and TRF2 
downregulation was coincident with Siah1 upregulation 
when p53 was overexpressed or nutlin-3a-activated 
[27]. The shRNA knockdown of Siah1 stabilized TRF2 
protein by extending its half-life and, most importantly, 
Siah1 was found to physically interact with and 
ubiquitinate TRF2 in a manner dependent on its RING 
finger domain [27]. These data identified Siah1 as an E3 
ubiquitin ligase that directly links p53 activation to 
TRF2 degradation, for the first time revealing that p53, 
a well-known downstream effector of the damage 
signaling from uncapped telomeres, also functions 
upstream to regulate a component of the telomere 
capping protein complex. Knockdown of endogenous 
Siah1 expression [27], as well as overexpression of 
TRF2 [32], delayed the onset of replicative senescence 
in human fibroblasts, suggesting that Siah1 co-operates 
with the other p53 target genes (e.g., p21
WAF1 and miR-
34a) [26] in p53-regulated senescence.  
 
TRF2-ATM-p53 positive feedback loop  
 
p53 is engaged in a number of positive and negative 
feedback loops to regulate carcinogenesis, aging and 
other biological processes [33]. p53 and MDM2, which 
is a p53-induced E3 ubiquitin ligase and targets p53 for 
ubiquitination and proteasomal degradation, form a 
minimum feedback unit that takes part in several larger 
and more complex feedback loops. These feedback 
loops also link the p53 signaling pathway to other signal 
transduction pathways, including those involving the 
cyclin E/cdk2 complex, the p38 MAP kinase, the 
WNT/β-catenin cascade and the PTEN/AKT cascade 
[33]. Given that TRF2 functions to negatively control 
ATM [12,13] (Figure 1, blue line) and that ATM 
phosphorylates and activates p53 [24] (Figure 1, green 
line), as described above, our finding of the p53-Siah1-
TRF2 pathway [27] (Figure 1, red lines) uncovers a 
novel feedback loop involving these factors: This 
TRF2-ATM-p53 feedback loop contains two inhibitory 
regulations (TRF2  ⊣  ATM and Siah1  ⊣ TRF2), thus 
functioning as a positive feedback mechanism (we 
would prefer the word “positive feedback”, rather than 
“double-negative feedback”, to indicate the functional 
consequence of the whole loop). Once telomere 
uncapping occurs either endogenously at the end of 
cellular replicative lifespan or exogenously by reagents 
and conditions inducing telomere dysfunction, 
diminished amount and/or impaired activity of TRF2 
results in ATM activation. ATM-mediated activation of 
p53 then transcriptionally activates Siah1, which 
ubiquitinates  and  degrades  TRF2,   leading  to  further  
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and reinforcement of the uncapped state of telomeres.  
 
The TRF2-ATM-p53 feedback loop amplifies telomere-
initiated, p53-mediated DNA damage responses leading 
to the rapid induction of cellular senescence or 
apoptosis, which may prevent DNA damage-carrying 
cells from contributing to tumor formation.  
 
Given the TRF2-ATM-p53 positive feedback loop, it is 
interesting to hypothesize that non-telomeric DNA 
damage and cellular stresses activating ATM and/or p53 
may induce telomere uncapping through the repression 
of TRF2 protein levels. Consistent with this hypothesis, 
our preliminary data showed that doxorubicin-induced 








































regulation of TRF2 [27]. It should also be noted that the 
TRF2-ATM-p53 positive feedback loop can 
functionally interact with the previously identified 
feedback regulations (Figure 1, black lines). β-catenin, 
another degradation target of Siah1 [30], is known to 
activate p19/p14ARF, which inhibits MDM2 and 
thereby activates p53 [34]. This regulatory circuit may 
act as a negative feedback element for the TRF2-ATM-
p53 positive feedback loop. While ATM can also 
activate p53 indirectly through the phosphorylation and  
inhibition of MDM2 [35], ATM-mediated phos-
phorylation of Siah1 may negatively affect its activity 
[36]. These co-operating and apparently opposing 
mechanisms are likely to add further strength and 
complexity to the DNA damage signaling from 
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Figure 1.  TRF2‐ATM‐p53 positive feedback loop.  TRF2 interacts with ATM and inhibits its
autophosphorylation and activation (blue line) [12,13]. ATM phosphorylates and activates p53
(green  line)  [23,24].  p53  transactivates  Siah1,  which  targets  TRF2  for  ubiquitination  and








Our identification of the p53- and Siah1-mediated 
regulation of TRF2 largely depended on in vitro 
experiments using normal human fibroblasts in culture. 
However, there is evidence that this regulation also 
exists in vivo. Human colon adenomas, a premalignant 
tumor in which p53-mediated cellular senescence is 
pathologically induced in vivo [37,38], were shown to 
express higher levels of Siah1 and lower levels of TRF2 
than normal non-senescent tissues [27], recapitulating 
the expression profile observed in senescent fibroblasts 
in vitro. Further studies will investigate the role of the 
TRF2-ATM-p53 feedback regulation in in vivo 
physiological senescence, aging-associated genome 
instability and organismal aging in humans.  
 
An attribution of cellular senescence, or aging at the 
cellular level, to aging at the organ and organismal 
levels can be explained by an aging-associated decline 
in stem cell function [39-41]. Accumulated DNA 
damage at telomeric and non-telomeric loci in tissue-
specific stem cells during aging could cause cellular 
senescence or apoptosis in those cells, leading to 
reduced tissue regeneration, impaired organ function 
and homeostasis, and eventually organismal senescence. 
Since a growing body of evidence suggests that p53 
activity and telomere integrity are critical to the 
regulation of self-renewing and differentiating 
properties of embryonic and adult stem cells [39,42-44], 
the TRF2-ATM-p53 positive feedback loop should have 
significant relevance to stem cell biology and stem cell-
based medicine.  
 
p53 is the most frequently inactivated gene in human 
cancer [45,46], and therefore p53 replacement or 
restoration therapy is a therapeutic strategy against 
cancer. Telomeres have also been a promising target for 
cancer therapy: telomerase inhibitors can induce short 
telomeres in cancer cells to be uncapped [18]; and G-
quadruplex ligands (e.g., telomestatin) reduce the 
amounts of G-rich 3’-overhang and remove POT1 and 
TRF2 from telomeric DNA, resulting in telomere 
uncapping [20,47]. We now know that these p53-based 
and telomere-based cancer therapies can co-operate in a 
single regulatory loop, namely the TRF2-ATM-p53 
positive feedback loop. We expect that our findings will 
be experimental basis for combined application of p53-
based therapy, telomere-based therapy and other 
strategies involving the associated factors such as β-
catenin, p19/p14ARF and MDM2.  
 
Some p53 missense mutations not only inhibit wild-type 
p53 activity but also gain a function that wild-type p53 
does not have. One of such gain-of-function activities of 
mutant p53 is to inhibit ATM [48], which allows cancer 
cells to abrogate the TRF2-ATM-p53 feedback 
regulation in a more active manner than simply losing 
or inactivating wild-type p53. It will be of therapeutic 
interest to investigate whether small molecules that 
restore wild-type function to mutant p53 (e.g., CP-
31398 and PRIMA-1) [49,50] can restore the TRF2-
ATM-p53 positive feedback regulation in cancers with 
p53 mutations. In cancers with wild-type p53, the 
expression of Δ133p53, a natural p53 isoform that 
inhibits wild-type p53 activity, is frequently elevated 
and thus Δ133p53 can be a therapeutic target [26]. 
Restoration of wild-type p53 activity by inhibition of 
Δ133p53 and the resulting degradation of TRF2 [26,27] 
may cause telomere uncapping-induced senescence or 
apoptosis through the TRF2-ATM-p53 positive 




p53 has long been linked to the regulation of telomeres. 
In the classical view of telomere length regulation, p53 
was a mediator of telomere-induced replicative 
senescence, as well as a negative regulator of 
telomerase via hTERT inhibition. Upon identification of 
the telomere-capping shelterin complex, p53 has been 
established as a downstream effector of the DNA 
damage signaling emerging from a specific shelterin 
component at uncapped telomeres. With evidence that 
p53 directly controls the shelterin component in a 
feedback manner, much attention to p53 continues to 
come from basic research on telomere biology, as well 
as from translational and clinical research aiming at 




We thank Drs. David Lane, Jean-Christophe Bourdon, 
Borivoj Vojtesek, Ettore Appella, Lisa M. Jenkins and 
Abdul M. Mondal for fruitful collaborations.  
 
CONFLICT OF INTERESTS STATEMENT 
 
The authors of this manuscript have no conflict of 






2.  Colgin  LM,  Reddel  RR.  Telomere  maintenance  mechanisms 
and cellular immortalization. Curr Opin Genet Dev. 1999; 9: 97‐
103. 
3.  Collins  K,  Mitchell  JR.  Telomerase  in  the  human  organism. 
Oncogene. 2002; 21: 564‐579. 
   
www.impactaging.com                    30                                        AGING, January 2011, Vol.3 No.14.  Horikawa  I,  Barrett  JC.  Transcriptional  regulation  of  the 
telomerase  hTERT  gene  as  a  target  for  cellular  and  viral 
oncogenic mechanisms. Carcinogenesis. 2003; 24: 1167‐1176. 
5.  Kanaya T, Kyo S, Hamada K, Takakura M, Kitagawa Y, Harada 













10.  Sfeir  AJ,  Chai  W,  Shay  JW,  Wright  WE.  Telomere‐end 




































p53:  cooperative  integrators  of  function.  Cold  Spring  Harb 
Perspect Biol. 2009; 1: a000950. 


















27.  Fujita  K,  Horikawa  I,  Mondal  AM,  Jenkins  LM,  Appella  E, 
Vojtesek B et al. Positive feedback between p53 and TRF2 during 
telomere‐damage  signalling  and  cellular  senescence.  Nat  Cell 
Biol. 2010; 12: 1205‐1212. 
28. Pedeux R, Sengupta S, Shen JC, Demidov ON, Saito S, Onogi H 
et  al.  ING2  regulates  the  onset  of  replicative  senescence  by 
induction  of  p300‐dependent  p53  acetylation.  Mol  Cell  Biol. 
2005; 25: 6639‐6648. 
29. Binet R, Ythier D, Robles AI, Collado M, Larrieu D, Fonti C et 
al.  WNT16B  is  a  new  marker  of  cellular  senescence  that 
regulates  p53  activity  and  the  phosphoinositide  3‐kinase/AKT 
pathway. Cancer Res. 2009; 69: 9183‐9191. 
30. Matsuzawa SI, Reed JC. Siah‐1, SIP, and Ebi collaborate in a 
novel  pathway  for  β‐catenin  degradation  linked  to  p53 
responses. Mol Cell. 2001; 7: 915‐926. 
31.  Tanikawa  J,  Ichikawa‐Iwata  E,  Kanei‐Ishii  C,  Nakai  A, 
Matsuzawa S, Reed JC et al. p53 suppresses the c‐Myb‐induced 
activation  of  heat  shock  transcription  factor  3.  J  Biol  Chem. 
2000; 275: 15578‐15585. 








pathway  and  overexpression  of  cyclin  D1  during  squamous 




p53  activation  by  DNA  damage.  Genes  Dev.  2001;  15:  1067‐
1077. 
36.  Winter  M,  Sombroek  D,  Dauth  I,  Moehlenbrink  J, 
Scheuermann  K,  Crone  J  et  al.  Control  of  HIPK2  stability  by 
ubiquitin ligase Siah‐1 and checkpoint kinases ATM and ATR. Nat 
Cell Biol. 2008; 10: 812‐824. 





interleukin‐dependent  inflammatory  network.  Cell.  2008;  133: 
1019‐1031. 
   
www.impactaging.com                    31                                        AGING, January 2011, Vol.3 No.139. Jaskelioff M, Muller FL, Paik JH, Thomas E, Jiang S, Adams AC 
et  al.  Telomerase  reactivation  reverses  tissue degeneration  in 
aged telomerase‐deficient mice. Nature. 2011; 469: 102‐106. 





Peit  E,  Hoffmann  E  et  al.  p53  deletion  impairs  clearance  of 
chromosomal‐instable  stem  cells  in  aging  telomere‐
dysfunctional mice. Nat Genet. 2009; 41: 1138‐1143. 
43. Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, Giulini B 
et  al.  The  tumor  suppressor  p53  regulates  polarity  of  self‐
renewing  divisions  in  mammary  stem  cells.  Cell.  2009;  138: 
1083‐1095. 
44. Nalapareddy K, Jiang H, Guachalla Gutierrez LM, Rudolph KL. 
Determining  the  influence  of  telomere  dysfunction  and  DNA 
damage on stem and progenitor cell aging: what markers can we 
use? Exp Gerontol. 2008; 43: 998‐1004. 
45.  Hollstein  M,  Sidransky  D,  Vogelstein  B,  Harris  CC.  p53 
mutations in human cancers. Science. 1991; 253: 49‐53. 





El  K,  V  et  al.  Telomestatin‐induced  telomere  uncapping  is 
modulated by POT1 through G‐overhang extension in HT1080 
human tumor cells. J Biol Chem. 2006; 281: 38721‐38729. 
48.  Song  H,  Hollstein  M,  Xu  Y.  p53  gain‐of‐function  cancer 
mutants induce genetic instability by inactivating ATM. Nat Cell 
Biol. 2007; 9: 573‐580. 
49.  Foster  BA,  Coffey  HA,  Morin  MJ,  Rastinejad  F. 
Pharmacological  rescue  of  mutant  p53  conformation  and 
function. Science. 1999; 286: 2507‐2510. 






www.impactaging.com                    32                                         AGING, January 2011, Vol.3 No.1